A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients

PLoS ONE

Volumn 2, Issue 7, 2007, Pages

  Brodsky, Leonid I ^a   Wahed, Abdus S ^c   Li, Jia ^c   Tavis, John E ^d   Tsukahara, Takuma ^b   Taylor, Milton W ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; INTERFERON REGULATORY FACTOR 7; RIBAVIRIN; RNA; VIRUS PROTEIN;

ARTICLE; BLOOD; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; METABOLISM; PATIENT SELECTION;

ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; RIBAVIRIN; RNA; VIRAL PROTEINS;

EID: 58149384064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000584     Document Type: Article

References (39)

1. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, et al.(2000) A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype, Am J Gastroenterol 95: 3225-3229.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al.(2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med 347: 975-982.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al.(2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet 358: 958-965.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al.(2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med 140: 346-355.
5. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al.(1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science 282: 103-107.
6. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, et al.(2001) Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a, Gastroenterology 120: 1438-1447.
7. Taylor MW, Grosse WM, Schaley JE, Sanda C, Wu X, et al.(2004) Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro, J Interferon Cytokine Res 24: 107-118.
8. Der SD, Zhou A, Williams BR, Silverman RH, (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays, Proc Natl Acad Sci U S A 95: 15623-15628.
9. de Veer MJ, Holko M, Frevel M, Walker E, Der S, et al.(2001) Functional classification of interferon-stimulated genes identified using microarrays, J Leukoc Biol 69: 912-920.
10. Tan H, Derrick J, Hong J, Sanda C, Grosse WM, et al.(2005) Global transcriptional profiling combination of type I and type II demonstrates the interferon enhances antiviral and immune responses at clinically relevant doses, J Interf Cytok Res 25: 632-649.
11. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, et al.(2007) Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy, J Virol 81: 3391-3401.
12. Alter O, Brown PO, Botstein D, (2000) Singular value decomposition for genome-wide expression data processing and modeling, Proc Natl Acad Sci U S A 97: 10101-10106.
13. Jail A, Dubes R, (1988) Algorithms for Clustering Data, Englewood Cliffs, NJ.USA Prentice Hall.
14. Pazos F, Valencia A, (2001) Similarity of phylogenetic trees as indicator of protein-protein interaction, Protein engineering 14: 609-614.
15. Gertz J, Elfond G, Shustrova A, Weisinger M, Pellegrini M, et al.(2003) Inferring protein interactions from phylogenetic distance matrices, Bioinformatics 19: 2039-2045.
16. Snedecor GW, Cochran WG, (1989) Statistical Methods. Ames Iowa University Press.
17. Cox T, Cox M, (2003) Multidimensional Scaling. Chapman and Hall.
18. Sanda C, Weitzel P, Tsukahara T, Schaley J, Edenberg HJ, et al.(2006) Differential Gene Induction by Type I and Type II Interferons and Their Combination, J Interferon Cytokine Res 26: 462-472.
19. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, et al.(2003) Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C, Hepatology 37: 610-621.
20. Samuel CE, (2001) Antiviral actions of interferons, Clin Microbiol Rev 14: 778-809, table of contents.
21. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, et al.(2004) Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection, J Biol Chem 279: 45194-45207.
22. Nguyen H, Hiscott J, Pitha PM, (1997) The growing family of interferon regulatory factors, Cytokine Growth Factor Rev 8: 293-312.
23. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al.(2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses, Nature 434: 772-777.
24. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, et al.(2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF, J Exp Med 198: 1043-1055.
25. Lim W, Gee K, Mishra S, Kumar A, (2005) Regulation of B7.1 costimulatory molecule is mediated by the IFN regulatory factor-7 through the activation of JNK in lipopolysaccharide-stimulated human monocytic cells, J Immunol 175: 5690-5700.
26. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, et al.(2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling, J Biol Chem 280: 17005-17012.
27. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, et al.(2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF, Proc Natl Acad Sci U S A 102: 2992-2997.
28. Sumpter R Jr, Loo YM, Foy E, Li K, Yoneyama M, et al.(2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I, J Virol 79: 2689-2699.
29. Johnson CL, Gale MJ Jr, (2006) CARD games between virus and host get a new player, Trends Immunol 27: 1-4.
30. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, et al.(2002) Genomic analysis of the host response to hepatitis C virus infection, Proc Natl Acad Sci U S A 99: 15669-15674.
31. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR, (2005) Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector, Hepatology 42: 702-710.
32. Dong B, Zhou Q, Zhao J, Zhou A, Harty RN, et al.(2004) Phospholipid scramblase 1 potentiates the antiviral activity of interferon, J Virol 78: 8983-8993.
33. Tahara E Jr, Tahara H, Kanno M, Naka K, Takeda Y, et al.(2005) G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell, Cancer Immunol Immunother 54: 729-740.
34. Yang H, Duckett CS, Lindsten T, (1995) iPABP, an inducible poly(A)-binding protein detected in activated human T cells, Mol Cell Biol 15: 6770-6776.
35. Okochi K, Suzuki T, Inoue J, Matsuda S, Yamamoto T, (2005) Interaction of anti-proliferative protein Tob with poly(A)-binding protein and inducible poly(A)-binding protein: implication of Tob in translational control, Genes Cells 10: 151-163.
36. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, et al.(2006) Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway, Cancer research 66: 921-928.
37. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, et al.(2001) Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations, Blood 97: 288-296.
38. van den Berg TK, Nath D, Ziltener HJ, Vestweber D, Fukuda M, et al.(2001) Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1), J Immunol 166: 3637-3640.
39. Oetke C, Vinson MC, Jones C, Crocker PR, (2006) Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels, Mol Cell Biol 26: 1549-1557.